Global Solid Organ Transplantation Market, By Organ (Kidney, Liver, Pancreas, Heart, Lung, Small Bowel, Kidney/Pancreas, Others), Product (Tissue Products, Immunosuppressive Drugs, Preservation Solution), Treatment (Immunosuppressive, Monoclonal Antibodies, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Solid Organ Transplantation Market Analysis and Size
The global solid organ transplantation market is expected to witness significant growth during the forecast period. Increasing demand for novel tissue transplantation products and organ transplantation for the treatment of organ failure is a foremost factor leading to the market growth. Unhealthy dietary habits, lack of exercise, alcohol consumption, and drug abuse are some important causes of organ failure. It has been witnessed that tissue products were the highest revenue-generating segment in 2021 having a market share of 57.8%. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global solid organ transplantation market in the forecast period 2022-2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Solid organ transplantation works like an advantage for patients suffering from end-stage kidney, pancreas, small intestine, heart, liver, and lung diseases. Although, it is not a process that improves survival, certain quality-of-life improvements are realized with vascular composite allograft and uterus transplantation. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Solid Organ Transplantation Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Organ (Kidney, Liver, Pancreas, Heart, Lung, Small Bowel, Kidney/Pancreas, Others), Product (Tissue Products, Immunosuppressive Drugs, Preservation Solution), Treatment (Immunosuppressive, Monoclonal Antibodies, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V (U.S.), Johnsons & Johnsons Services Inc (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Lilly (U.S.), Merck & Co., Inc. (U.S.), Aurobindo Pharma (India), Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), Ascendis Pharma A/S (Denmark), LEO Pharma A/S (Denmark), Genentech, Inc (U.S.), Celltrion Inc (South Korea)
|
|
Market Opportunities
|
|
Global Solid Organ Transplantation Market Dynamics
Drivers
- Growing Demand for Organ Transplant
The global rise in the organ transplant demand can be attributed to an increase in the occurrence of acute diseases, which in turn leads to an increase in the number of organ failures. For instance, diabetes and high blood pressure are considered to be the most common causes of end-stage renal disease, wherein kidney transplants or dialysis are the only treatment options to keep a patient alive. As per the records of the U.S. Department of Health & Human Services, about 122,913 patients in the U.S. were waiting to receive organs for transplant in 2019. Thus, the demand for advanced transplantation products for the treatment of organ failure is high.This boosts the market growth.
- Technological Advancements
Several technological advancemnets in this sector are expected to boost the growth of the market. For instance, in September 2015, Arthrex Inc. launched ArthroFlex Acellular Dermal Matrix, a new orthobiologic product proposed for use in capsular reconstruction. This product allows preservation of its growth factors and native collagen scaffold and elastin and permits transplant to be successfully incorporated into the recipient. All these factors boost the market growth.
Opportunities
- Higher Mergers and Acquisitions
Several manufacturers are aiming on new product development, mergers & acquisition, and collaborations to enlarge their current product portfolio and maintain their persistent position in the market. For instance, in September 2016, Stryker Corporation announced the acquisition of Instratek. It is a top manufacturer of minimally invasive soft tissue recession instruments for ankle, foot, and upper extremity procedures.
- Increasing Sales of Immunosuppressive Drugs
Tissue products for transplantation accounted for the largest share in 2021, and this category is projected to maintain its position in the upcoming future due to the increasing use of orthobiologics in orthopedic procedures for normal functioning restoration, tissue healing, and pain minimization, combined with the increasing elderly population across the globe. Moreover, startup companies in this field are receiving investments to expand their business. Thus, this factor is creating much opportunities for the market growth.
Restraints/Challenges
- High Cost
The huge association with organ transplantation and many other immunosuppressive drugs restrain the market growth.
- Unavailability of Treatment
Not all the treatments are available in all the countries which restrict the market growth. There are several underdeveloped countries wherein the modified treatments are not available. Thus, it restricts the growth of the market.
This global solid organ transplantation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global solid organ transplantation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Solid Organ Transplantation Market
There has been a significant proportion of coronavirus patients who were hospitalized in medical centers, governing bodies were bound to restrict to these patients. The pandemic also caused a drip in organ transplant surgery enrolment globally.
The reduction in the number of transplantation and organ donation procedures is mostly because of factors such as engaged surgeons, unavailability of resources, lockdown, and travel restrictions. Patients having positive reports for COVID-19 were restricted from donating organs because of the possibility of infection. Additionally, another major concern prompting transplantation operations was the possibility of immunosuppressant drug interactions with COVID-19 therapy agents, which had led to a substantial number of organ failures from graft donors.
Recent Development:
- In November 2020, Lupin launched a generic immunosuppressant drug, Tacrolimus in the U.S. market which is indicated for prophylaxis of organ rejection in the allogeneic liver, kidney, and heart transplant.
Global Solid Organ Transplantation Market Scope
The global solid organ transplantation market is segmented on the basis of organ, product, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Organ
- Kidney
- Liver
- Pancreas
- Heart
- Lung
- Small Bowel
- Kidney/Pancreas
- Others
Product
- Tissue Products
- Immunosuppressive Drugs
- Preservation Solution
Treatment
- Immunosuppressive
- Monoclonal Antibodies
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Solid Organ Transplantation Market Regional Analysis/Insights
The global solid organ transplantation market is analysed and market size insights and trends are provided by organ, product, treatment, distribution channel and end-user as referenced above.
The major countries covered in the global solid organ transplantation market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the presence of key manufacture of the product and increased healthcare and R & D expenditure.
Asia-Pacific dominates the market due to increased prevalence of organ failure, and presence of generic drugs manufacturers.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Solid Organ Transplantation Market Share Analysis
The global solid organ transplantation market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global solid organ transplantation market.
Key players operating in the global solid organ transplantation market include:
- Teva Pharmaceutical Industries Ltd (Israel)
- Mylan N.V (U.S.)
- Johnsons & Johnsons Services Inc (U.S.)
- F. Hoffman-La Roche Ltd. (Switzerland)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Aurobindo Pharma (India)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc (U.K.)
- Ascendis Pharma A/S (Denmark)
- LEO Pharma A/S (Denmark)
- Genentech, Inc (U.S.)
- Celltrion Inc (South Korea)
SKU-